白癜风样小鼠皮肤脱色模型研究进展与思考

doi:10.35541/cjd.20220072

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (7): 622-628.doi: 10.35541/cjd.20220072

白癜风样小鼠皮肤脱色模型研究进展与思考

坚哲张甲

第四军医大学西京皮肤医院，西安 710032

收稿日期:2022-01-26 修回日期:2022-05-25 发布日期:2022-07-05
通讯作者: 张甲 E-mail:362014063@qq.com
基金资助:
国家自然科学基金（81872521、82173414）；空军军医大学凌云工程翱翔计划项目（Axjhjz-102）

Research progress and thinking in mouse models of vitiligo-like depigmentation

^{Jian Zhe, Zhang Jia}

Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China

Received:2022-01-26 Revised:2022-05-25 Published:2022-07-05
Contact: Zhang Jia E-mail:362014063@qq.com
Supported by:
National Natural Science Foundation of China （81872521, 82173414）; Aoxiang Program in Lingyun Project of Air Force Military Medical University （Axjhjz-102）

摘要/Abstract

摘要： 【摘要】白癜风的病因及发病机制均未明确，动物模型是白癜风研究的重要工具。除传统的白癜风小鼠模型外，许多新模型逐渐建立，如表达表皮黑素细胞、黑素细胞反应性T细胞的小鼠模型、K14-SCF/h3TA2/HLA-A2三转基因（Vitesse鼠）小鼠模型、自身免疫诱导的小鼠模型、化学试剂诱导的小鼠模型等，这些模型与人白癜风高度相似，在可重复性和稳定性等方面都有不同程度提高，已成为研究白癜风发病机制、探索治疗靶点和评判疗效的良好模型。本文综述目前白癜风样小鼠脱色模型的研究进展，并分析存在的问题。

关键词: 白癜风, 黑素细胞, 疾病模型, 动物

Abstract: 【Abstract】 The etiology and pathogenesis of vitiligo have not yet been clear, and animal models are important tools for vitiligo research. In addition to traditional mouse models of vitiligo, many new models have been gradually established with the deepening of research, such as mouse models expressing epidermal melanocytes and melanocyte-reactive T cells, K14-SCF/h3TA2/HLA-A2 triple-transgenic mouse (Vitesse mice) models, autoimmune-induced mouse models, chemical reagent-induced mouse models, etc. Manifestations of these models are highly similar to human vitiligo, their reproducibility and stability have been improved to different extents, and they have already become good models for exploring the pathogenesis of and therapeutic targets for vitiligo, as well as for evaluating therapeutic efficacy. This review summarizes current research progress and existing problems in mouse models of vitiligo-like depigmentation.

Key words: Vitiligo, Melanocytes, Disease models, animal

坚哲张甲. 白癜风样小鼠皮肤脱色模型研究进展与思考[J]. 中华皮肤科杂志, 2022,55(7):622-628. doi:10.35541/cjd.20220072

Jian Zhe, Zhang Jia. Research progress and thinking in mouse models of vitiligo-like depigmentation[J]. Chinese Journal of Dermatology, 2022, 55(7): 622-628.doi:10.35541/cjd.20220072

参考文献 39

［1］	Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo［J］. Lancet, 2015,386（9988）:74⁃84. doi: 10.1016/S0140⁃6736（14）60763⁃7.
［2］	Tokura Y, Fujiyama T, Ikeya S, et al. Biochemical, cytological, and immunological mechanisms of rhododendrol⁃induced leukoderma［J］. J Dermatol Sci, 2015,77（3）:146⁃149. doi: 10. 1016/j.jdermsci.2015.02.001.
［3］	Abe Y, Okamura K, Kawaguchi M, et al. Rhododenol⁃induced leukoderma in a mouse model mimicking Japanese skin［J］. J Dermatol Sci, 2016,81（1）:35⁃43. doi: 10.1016/j.jdermsci.2015. 10.011.
［4］	Kunisada T, Lu SZ, Yoshida H, et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor［J］. J Exp Med, 1998,187（10）:1565⁃1573. doi: 10.1084/jem.187.10.1565.
［5］	Ito S, Okura M, Nakanishi Y, et al. Tyrosinase⁃catalyzed metabolism of rhododendrol （RD） in B16 melanoma cells: production of RD⁃pheomelanin and covalent binding with thiol proteins［J］. Pigment Cell Melanoma Res, 2015,28（3）:295⁃306. doi: 10.1111/pcmr.12363.
［6］	Hayashi M, Okamura K, Abe Y, et al. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol⁃induced vitiligo［J］. J Dermatol, 2019,46（6）:548⁃550. doi: 10.1111/1346⁃8138.14879.
［7］	Tsutsumi R, Sugita K, Abe Y, et al. Leukoderma induced by rhododendrol is different from leukoderma of vitiligo in pathogenesis: a novel comparative morphological study［J］. J Cutan Pathol, 2019,46（2）:123⁃129. doi: 10.1111/cup.13396.
［8］	Zhu Y, Wang S, Xu A. A mouse model of vitiligo induced by monobenzone［J］. Exp Dermatol, 2013,22（7）:499⁃501. doi: 10.1111/exd.12184.
［9］	van den Boorn JG, Konijnenberg D, Tjin EP, et al. Effective melanoma immunotherapy in mice by the skin⁃depigmenting agent monobenzone and the adjuvants imiquimod and CpG［J/OL］. PLoS One, 2010,5（5）:e10626. doi: 10.1371/journal.pone.0010626.
［10］	Westerhof W, Manini P, Napolitano A, et al. The haptenation theory of vitiligo and melanoma rejection: a close⁃up［J］. Exp Dermatol, 2011,20（2）:92⁃96. doi: 10.1111/j.1600⁃0625.2010. 01200.x.
［11］	van den Boorn JG, Melief CJ, Luiten RM. Monobenzone⁃induced depigmentation: from enzymatic blockade to autoimmunity［J］. Pigment Cell Melanoma Res, 2011,24（4）:673⁃679. doi: 10.1111/j.1755⁃148X.2011.00878.x.
［12］	van den Boorn JG, Picavet DI, van Swieten PF, et al. Skin⁃depigmenting agent monobenzone induces potent T⁃cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy［J］. J Invest Dermatol, 2011,131（6）:1240⁃1251. doi: 10.1038/jid.2011.16.
［13］	Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self⁃reactive CD8+ T cells［J］. J Exp Med, 2003,198（4）:569⁃580. doi: 10.1084/jem.20030590.
［14］	Harris JE. Chemical⁃induced vitiligo［J］. Dermatol Clin, 2017,35（2）:151⁃161. doi: 10.1016/j.det.2016.11.006.
［15］	Mansourpour H, Ziari K, Motamedi SK, et al. Therapeutic effects of iNOS inhibition against vitiligo in an animal model［J］. Eur J Transl Myol, 2019,29（3）:8383. doi: 10.4081/ejtm.2019.8383.
［16］	祝逸平, 王遂泉, 李阳, 等. 局部针刺对莫诺苯宗诱导C57BL/6小鼠白癜风样模型的影响［J］. 中华皮肤科杂志, 2014,47（1）:26⁃29. doi: 10.3760/cma.j.issn.0412⁃4030.2014.01.008.
［17］	李情, 祝逸平, 许爱娥. 茶多酚、吡美莫司、他克莫司外用对莫诺苯宗诱导白癜风样模型小鼠的疗效比较［J］. 中华皮肤科杂志, 2015,48（1）:41⁃44. doi: 10.3760/cma.j.issn.0412⁃4030. 2015.01.014.
［18］	Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer［J］. J Leukoc Biol, 2004,76（2）:333⁃337. doi: 10.1189/jlb.0304120.
［19］	Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"⁃reactive, tumoricidal T cells using high⁃affinity, altered peptide ligand［J］. J Exp Med, 1998,188（2）:277⁃286. doi: 10.1084/jem.188. 2.277.
［20］	Klebanoff CA, Finkelstein SE, Surman DR, et al. IL⁃15 enhances the in vivo antitumor activity of tumor⁃reactive CD8+ T cells［J］. Proc Natl Acad Sci U S A, 2004,101（7）:1969⁃1974. doi: 10.1073/pnas.0307298101.
［21］	Riding RL, Richmond JM, Harris JE. Mouse model for human vitiligo［J］. Curr Protoc Immunol, 2019,124（1）:e63. doi: 10. 1002/cpim.63.
［22］	Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis［J］. J Invest Dermatol, 1998,111（2）:233⁃238. doi: 10.1046/j.1523⁃1747.1998.00272.x.
［23］	Wehrle⁃Haller B. The role of Kit⁃ligand in melanocyte development and epidermal homeostasis［J］. Pigment Cell Res, 2003,16（3）:287⁃296. doi: 10.1034/j.1600⁃0749.2003.00055.x.
［24］	Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem⁃cell fate determination［J］. Nature, 2002,416（6883）:854⁃860. doi: 10.1038/416854a.
［25］	Nishimura EK, Yoshida H, Kunisada T, et al. Regulation of E⁃ and P⁃cadherin expression correlated with melanocyte migration and diversification［J］. Dev Biol, 1999,215（2）:155⁃166. doi: 10.1006/dbio.1999.9478.
［26］	Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild⁃type melanocyte⁃lineage antigens rescues suboptimal immune checkpoint blockade responses［J］. Sci Transl Med, 2021,13（581）: eabd8636. doi: 10.1126/scitranslmed.abd8636.
［27］	Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab［J］. JAMA Dermatol, 2016,152（1）:45⁃51. doi: 10.1001/jamadermatol.2015.2707.
［28］	Herzberg B, Fisher DE. Metastatic melanoma and immunotherapy［J］. Clin Immunol, 2016,172:105⁃110. doi: 10. 1016/j.clim.2016.07.006.
［29］	Turk MJ, Guevara⁃Patiño JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells［J］. J Exp Med, 2004,200（6）:771⁃782. doi: 10.1084/jem.20041130.
［30］	Xu Z, Chen D, Hu Y, et al. Anatomically distinct fibroblast subsets determine skin autoimmune patterns［J］. Nature, 2022,601（7891）:118⁃124. doi: 10.1038/s41586⁃021⁃04221⁃8.
［31］	Halprin KM. Epidermal "turnover time"⁃⁃a re⁃examination［J］. Br J Dermatol, 1972,86（1）:14⁃19. doi: 10.1111/j.1365⁃2133. 1972.tb01886.x.
［32］	Gregg RK, Nichols L, Chen Y, et al. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase⁃specific TCR transgenic mice［J］. J Immunol, 2010,184（4）:1909⁃1917. doi: 10.4049/jimmunol.0902778.
［33］	Nichols LA, Chen Y, Colella TA, et al. Deletional self⁃tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio⁃resistant cell in peripheral and mesenteric lymph nodes［J］. J Immunol, 2007,179（2）:993⁃1003. doi: 10. 4049/jimmunol.179.2.993.
［34］	Eby JM, Kang HK, Klarquist J, et al. Immune responses in a mouse model of vitiligo with spontaneous epidermal de⁃ and repigmentation［J］. Pigment Cell Melanoma Res, 2014,27（6）:1075⁃1085. doi: 10.1111/pcmr.12284.
［35］	Eby JM, Kang HK, Tully ST, et al. CCL22 to activate Treg migration and suppress depigmentation in vitiligo［J］. J Invest Dermatol, 2015,135（6）:1574⁃1580. doi: 10.1038/jid.2015.26.
［36］	Mehrotra S, Al⁃Khami AA, Klarquist J, et al. A coreceptor⁃independent transgenic human TCR mediates anti⁃tumor and anti⁃self immunity in mice［J］. J Immunol, 2012,189（4）:1627⁃1638. doi: 10.4049/jimmunol.1103271.
［37］	Oyarbide⁃Valencia K, van den Boorn JG, Denman CJ, et al. Therapeutic implications of autoimmune vitiligo T cells［J］. Autoimmun Rev, 2006,5（7）:486⁃492. doi: 10.1016/j.autrev.2006. 03.012.
［38］	Wang S, Zhou M, Lin F, et al. Interferon⁃γ induces senescence in normal human melanocytes［J/OL］. PLoS One, 2014,9（3）:e93232. doi: 10.1371/journal.pone.0093232.
［39］	Dell′anna ML, Cario⁃André M, Bellei B, et al. In vitro research on vitiligo: strategies, principles, methodological options and common pitfalls［J］. Exp Dermatol, 2012,21（7）:490⁃496. doi: 10.1111/j.1600⁃0625.2012.01506.x.

[1]	李柏樟亢盼张肖莹朱冠男李舒丽李春英. 白癜风共病糖尿病风险预测模型的构建及验证[J]. 中华皮肤科杂志, 2022, 55(7): 576-582.
[2]	蓝晓婕赵阳万世芳蔡志成王兴旺杨慧兰. 自噬对水痘-带状疱疹病毒感染豚鼠背根神经节模型中病毒结构及功能蛋白表达的影响[J]. 中华皮肤科杂志, 2022, 55(6): 494-500.
[3]	艾尼瓦尔·塔力甫熊成热甫哈提·赛买提玉苏甫·买提努尔吐尔逊·吾甫尔阿肯木江·艾尔肯居来提·阿不都瓦衣提买买提艾力·卡的. 采用生物信息学方法筛选和分析白癜风差异表达基因[J]. 中华皮肤科杂志, 2022, 55(5): 421-425.
[4]	付超吴姣娜郎文超高菲牛贵业边培雯高敏虹司晓青辛琳琳. 皮肤镜检查在评估白癜风疾病活动性中的作用[J]. 中华皮肤科杂志, 2022, 55(3): 268-271.
[5]	雷杰豪洪为松林福全胡文婷许爱娥. 体外培养节段型白癜风样无色素痣皮损黑素细胞及其临床意义[J]. 中华皮肤科杂志, 2022, 0(2): 20210350-e20210350.
[6]	竞艳费文敏李承旭崔勇. 多磺酸黏多糖乳膏对兔耳增生性瘢痕的抑制作用及机制研究[J]. 中华皮肤科杂志, 2022, 0(2): 20210690-e20210690.
[7]	栾超胡煜陈崑张家安顾恒张荣林张小华田盼盼朱艳庄晨黄丹鞠梅. 308 nm SQ LED光与308 nm准分子光治疗面部白癜风的疗效及安全性回顾性研究[J]. 中华皮肤科杂志, 2022, 55(1): 16-19.
[8]	姚晓东崔晓美刘晓宇吴晓琰沈聪聪陈晓栋. 长链非编码RNA 068在黑素瘤细胞迁移中的功能研究[J]. 中华皮肤科杂志, 2022, 55(1): 31-39.
[9]	陈怡, 宋秀祖. 瞬时受体电位通道在黑素细胞中的作用及相关疾病研究[J]. 中华皮肤科杂志, 2022, 0(1): 20200958-e20200958.
[10]	兰晓鸥王强李上云孙晓冬宋丹阳李佳蔚宋国强胡兰廷耿龙. 外用紫草素对咪喹莫特诱导银屑病样小鼠模型的干预作用及对CEBPD表达的影响[J]. 中华皮肤科杂志, 2021, 54(8): 696-701.
[11]	高飞谈园马乐黄敖张帅罗宏. 新西兰兔感染梅毒螺旋体体内扩散模型构建[J]. 中华皮肤科杂志, 2021, 54(8): 702-704.
[12]	郭丽芳葛一平杨寅林彤. 面部白癜风人工智能诊断模型的建立及评价[J]. 中华皮肤科杂志, 2021, 54(7): 586-589.
[13]	门月华韩慧璞艾克德·阿力甫姚义凡黄婷婷康佳蕊王铁山张明波鞠延娇初明王月丹. 2，4-二硝基氯苯诱导的特应性皮炎样小鼠模型的皮肤菌群特征研究[J]. 中华皮肤科杂志, 2021, 54(7): 605-611.
[14]	应洁雅相文忠宋秀祖. 代谢综合征与皮肤病[J]. 中华皮肤科杂志, 2021, 54(7): 642-645.
[15]	王晓宇王文慧戴慧谢嘉伟王冠钰郭金竹张华王秀娟徐永胜张春雷. 人脐带间充质干细胞对咪喹莫特诱导的银屑病样皮炎小鼠模型的治疗作用[J]. 中华皮肤科杂志, 2021, 54(6): 485-492.

白癜风样小鼠皮肤脱色模型研究进展与思考

Research progress and thinking in mouse models of vitiligo-like depigmentation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

Metrics

本文评价

推荐阅读 10